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Abstract: Paclitaxel (Taxol) resistance remains a major obstacle for the successful treatment 
of ovarian cancer. MicroRNAs (miRNAs) have oncogenic and tumor suppressor activity and 
are associated with poor prognosis phenotypes. miRNA screenings for this drug resistance 
are needed to estimate the prognosis of the disease and find better drug targets. miRNAs 
that were differentially expressed in Taxol-resistant ovarian cancer cells, compared with 
Taxol-sensitive cells, were screened by Illumina Human MicroRNA Expression BeadChips. 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to identify 
target genes of selected miRNAs. Kaplan–Meier survival analysis was applied to identify 
dysregulated miRNAs in ovarian cancer patients using data from The Cancer Genome Atlas. 
A total of 82 miRNAs were identified in ovarian carcinoma cells compared to normal ovarian 
cells. miR-141, miR-106a, miR-200c, miR-96, and miR-378 were overexpressed, and miR-411, 
miR-432, miR-494, miR-409-3p, and miR-655 were underexpressed in ovarian cancer cells. 
Seventeen miRNAs were overexpressed in Taxol-resistant cells, including miR-663, miR-622, 
and HS_188. Underexpressed miRNAs in Taxol-sensitive cells included miR-497, miR-187, 
miR-195, and miR-107. We further showed miR-663 and miR-622 as significant prognosis 
markers of the chemo-resistant patient group. In particular, the downregulation of the two 
miRNAs was associated with better survival, perhaps increasing the sensitivity of cancer cells 
to Taxol. In the chemo-sensitive patient group, only miR-647 could be a prognosis marker. These 
miRNAs inhibit several interacting genes of p53 networks, especially in TUOS-3 and TUOS-4, 
and showed cell line-specific inhibition effects. Taken together, the data indicate that the three 
miRNAs are closely associated with Taxol resistance and potentially better prognosis factors. 
Our results suggest that these miRNAs were successfully and reliably identified and would be 
used in the development of miRNA therapies in treating ovarian cancer.
Keywords: microRNA, ovarian cancer, Taxol resistance, Kaplan–Meier survival analysis
Introduction
Ovarian cancer is one of the deadliest malignancies, and is characterized by succes-
sive accumulation of multiple molecular alterations in the cells undergoing neoplastic 
transformation.1 At the time of diagnosis, most ovarian cancer patients have advanced 
stage disease (ie, stage III-IV) where the 5-year survival rate has remained unchanged 
for over 50 years partly due to the development of platinum and paclitaxel (Taxol; 
Bristol-Myers Squibb Co., New York, NY, USA) resistance.2,3 The nature of this 
drug resistance still remains a major obstacle for the successful treatment of ovarian 
cancer. Thus, screening for the drug-resistant factors is important in determining 
disease prognosis.
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Table 1 characteristics of ovarian cancer cell lines
Names Histologic type Origin Taxol 
resistance
iOse386
iOse397
normal ovarian  
epithelial cell
normal ovarian  
epithelial cell
a2780
a2780Tax
serous carcinoma
serous carcinoma
ascites
ascites
sensitive
resistant
KF serous adenocarcinoma Tumor sensitive
KFrTax
sKOV3
serous adenocarcinoma
serous adenocarcinoma
Tumor
ascites
resistant
sensitive
sKOV3Tax
TUOs3
serous adenocarcinoma
serous adenocarcinoma
ascites
Tumor
resistant
sensitive
TUOs4
TU-Oc-1
serous adenocarcinoma
clear cell
Tumor
Tumor
resistant
sensitive
OVcar-3 serous adenocarcinoma ascites sensitive
OV2008
c13
serous carcinoma- 
derived cell
serous  
cystadenocarcinoma
endometrioid
endometrioid
sensitive
sensitive
KK
KOc-2s
clear cell
serous adenocarcinoma
ascites
Tumor
resistant
resistant
KOc-7c clear cell Tumor resistant
OVcar3-Tx serous adenocarcinoma Tumor resistant
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MicroRNAs (miRNAs) may have oncogene-like or tumor 
suppressor-like  functions.4,5 Aberrant miRNA expressions 
have been found in many human cancers,6 and previous stud-
ies have focused on apoptosis,7 cell cycle,8 angiogenesis,9 
epithelial-to-mesenchymal transition (EMT),10 and chemo-
resistance.11 Upregulation of miR-451 increases cisplatin 
sensitivity of the non-small-cell lung cancer cell line (NSCLC) 
A549.12 miR-200c induces cisplatin chemoresistance in 
esophageal cancers through interaction with the AKT signal-
ing pathway.13 miR-125b is upregulated in Taxol-resistant cells 
and targets the pro-apoptotic Bcl-2 antagonist killer 1 (Bak1), 
inhibiting apoptosis and causing a subsequent increase in the 
resistance to Taxol in cancer cells.14
These studies highlight the need to study miRNAs that 
are involved in drug resistance in ovarian cancers. However, 
conflicting data have been reported about their potential func-
tions due to highly tissue-specific expression patterns.3 Using 
miRNA microarray analysis, for example, overexpression 
of miR-200 was reported as having association with poor 
or better prognosis in patients with ovarian cancer.15,16 Cur-
rently, there are no clinical implementations of differentially 
expressed miRNAs involved in the function of drug resistance 
in ovarian cancer, mainly because their validity has not yet 
been well established.
In this study, we employed miRNA expression profiling 
to identify differentially expressed miRNAs in Taxol-resistant 
ovarian cancer cells compared with Taxol-sensitive ovarian 
cancer cells. Ten profiling arrays were used and significant 
miRNAs were identified as prognosis markers through Kaplan–
Meier survival analysis.17 For the confirmation of differential 
expression of miRNAs, quantitative real-time PCR (qRT-PCR) 
was performed for target miRNAs and showed a good agree-
ment with the microarray assay. Also, Kaplan–Meier survival 
analyses as an integration-based approach were applied to 
identify dysregulated miRNAs in ovarian cancer using data 
from The Cancer Genome Atlas (TCGA).18 We first identified 
that three miRNAs, miR-663, miR-622, and miR-647, were 
significantly regulated in Taxol resistance. We also found that 
miRNA-663 and -622 increased the sensitivity of cancer cells 
to Taxol in ovarian cancer patients correlated with the better 
prognostic group. Our results could be used as a novel class of 
biomarkers for the further study of the molecular mechanism 
underlying Taxol resistance in ovarian cancer.
Materials and methods
cell lines and culture
Sixteen human ovarian cancer cell lines and two human nor-
mal ovarian cell lines (IOSE386, IOSE397) were used in this 
study (Table 1). Most of the cell lines were kindly provided 
by Dr Hiroaki Itamochi,19 Department of Obstetrics and 
 Gynecology, Tottori University, Tottori, Japan; IOSE386 and 
IOSE397 were from Dr Nelly Auersperg,20 Department of 
Obstetrics and Gynecology, University of British Columbia, 
Vancouver, BC, Canada; and SKOV3 was from Dr Ie-Ming 
Shih,21 Department of Gynecology and Obstetrics, The Johns 
Hopkins Hospital, Baltimore, MD, USA. Most of the cells 
were maintained in Roswell Park Memorial Institute (RPMI)-
1640 medium (Sigma-Aldrich, St Louis, MO, USA) with 
10% fetal bovine serum (FBS) in a humidified atmosphere 
containing 5% CO
2
 at 37°C. TUOS-3 and TUOS-4 cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM)/
F12 medium (Sigma-Aldrich) with 10% FBS, and in 5% 
CO
2
 at 37°C. IOSE386 and IOSE397 cells were maintained 
in DMEM medium with 10% FBS in 10% CO
2
 at 37°C. For 
the cell maintaining, both Taxol-sensitive and -resistant cell 
lines were used in their passage number ∼15s.
Viability assay
To evaluate sensitivity to Taxol, the cells were washed with 
fresh medium and exposed to Taxol (10 nm, 50 nM, 100 
nM, 200 nM, 500 nM, and 1,000 nM). The cells were then 
further incubated at 37°C for 3 days. After incubation with 
Taxol for 3 days, 100 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (2 mg/mL) was 
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added to each well and cultured for 4 hours. The viability 
assays was conducted as described previously.22 The insoluble 
product formed by viable cells was dissolved by the addition 
of 100 µL of dimethyl sulfoxide (DMSO) to each well for 
10 minutes. The absorbance was measured with a Spectra-
Max 340 automated spectrophotometric microtiter plate 
reader (Molecular Devices, Sunnyvale, CA, USA) using a 
570 nm filter. The morphological changes of the cells were 
determined by optical microscopy. A statistical difference of 
P,0.05 was considered significant.
miRNA expression profiling
Total RNA was extracted from cells using TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA). Two hundred nanograms 
of total RNA from each cell line were labeled and hybridized 
on Human v2 MicroRNA Expression BeadChips (Illumina, 
San Diego, CA, USA), according to the manufacturer recom-
mendations (Illumina MicroRNA Expression Profiling Assay 
Guide).23 The raw intensity of the Illumina v2 MicroRNA 
expression array was scanned and extracted using BeadScan 
(Illumina), with the data corrected by background subtrac-
tion in GenomeStudio (Illumina).24 The lumi package in the 
R-based Bioconductor Package was used to normalize the 
log2 transformed intensity data with the Quantile normal-
ization algorithm. For data quality control, we excluded the 
probes with detection P.0.05 (the P-values were generated 
in BeadStudio  software) across 75% of the samples. Probe 
mapping for Illumina MicroRNA Expression v2 BeadChips 
was based on miRBase (v.12.0; Faculty of Life Sciences, 
University of Manchester, Manchester, UK).25 For each 
comparison, we obtained the list of differentially expressed 
miRNA constrained by P,0.05 and then checked for can-
didates with at least 1.5-fold expression change. Hierarchi-
cal clustering based on the average linkage was employed. 
Using MiRTar (http://mirtar.mbc.nctu.edu.tw/human/) and 
PicTar (http://pictar.mdc-berlin.de/), we obtained the list 
of genes predicted to be targeted by the miRNAs identified 
from each comparison.
qrT-Pcr analysis
Total RNA was isolated from cells according to the 
manufacturer’s recommendations using TRIzol and the 
 Absolutely RNA kit from Stratagene (LaJolla, CA, USA). 
Total RNA (2 µg) was reverse transcribed in a total volume 
of 20 µL using 200 U of Superscript II reverse transcriptase 
 (Invitrogen), 100 pmol oligo-dT, 0.5 mM dNTP, and 40 
U RNasin  (Promega, Madison, WI, USA). The resulting 
complementary (c)DNA was diluted 1:10 with nuclease-
free water. Five microliters of diluted cDNA was used in 
subsequent PCR reactions. The PCR amplification protocol 
was 50°C for 2 minutes and 95°C for 10 minutes followed 
by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, 
and 72°C for 30 seconds. The real-time PCR analysis was 
performed on a C1000™ Thermal Cycler (CFX 96™ Real-
Time System, BioRad, Munich, Germany). All qRT-PCR 
reactions were carried out in triplicate.  Relative quantification 
with the data obtained was performed according to the user’s 
manual. The results are presented as transcript levels relative 
to the levels in untreated control cells with average mRNA 
levels of internal control gene, glyceraldehyde-3-phosphate 
dehydrogenase, used as the normalization control. To verify 
changes in gene expression, real-time PCR was carried out 
on selected genes. All primers were designed based on nucle-
otide sequences retrieved from Genbank using the Primer 
Express software (Applied Biosystems, Foster City, CA, 
USA). The fold-change (ratio) in gene expression between 
cancer samples and normal samples was calculated by using 
threshold cycle (C
T
).22 All primer sequences are provided in 
Table S1.
qrT-Pcr analysis of mirna expression
qRT-PCR was performed on the selected miRNA candidates 
to validate the miRNA array results. The GenoExplorer 
miRNA First-Strand cDNA Core Kit (2002-50, GenoSensor 
Corporation, Tempe, AZ, USA) was used to generate miRNA 
first-strand complementary DNA. miRNA expression levels 
were measured using SYBR Green (Takara, Kyoto, Japan). 
miRNA-specific forward primers and a universal reverse 
primer were purchased (GenoSensor Corporation). The 
reaction conditions were 15 minutes of denaturation at 94°C 
followed by 45 cycles of 94°C for 30 seconds, 59°C for 
15 seconds, and 72°C for 30 seconds. Melting curve analysis 
was used to assess the specificity of the amplified product. All 
qRT-PCR reactions were carried out in triplicate. Threshold 
cycle (C
T
) for each miRNA was obtained after normalizing 
to U6 snRNA Forward (5′-CTCGCTTCGGCAGCACA-3′) 
and Reverse (5′-AACGCTTCACGAATTTGC GT-3′).
analysis of the Tcga data for ovarian 
cancer
Ovarian cancer TCGA miRNA microarray data of level 
3 were obtained from the Data Access Matrix (http://
tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).26 miRNA 
experiments were performed on the Agilent 8 × 15 K 
human miRNA-specific microarray V2 platform (Santa 
Clara, CA, USA) measuring the expression of 821 miRNAs. 
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Five hundred and ninety-five TCGA miRNA data with 
clinical information were reprocessed using the R statistical 
computing platform and packages from the Bioconductor 
bioinformatics software project (http://www.r-project.org). 
Of these, we retained only 479 samples that had clinical 
information data. Two independent filters were applied 
to miRNAs to remove low-level signal intensity or not 
expression in ovarian cancer tissue. In the first, miRNAs 
with ,10% “present” and “marginal” calls were removed. 
In the second, miRNAs containing .10% of accumulated 
zeros across samples were removed.  miRNAs that were sig-
nificantly changed were analyzed further. A t-test assessed 
whether the means of the two groups were statistically dif-
ferent from each other. Then, we performed unsupervised 
and supervised hierarchical clustering based on the most 
variably expressed miRNAs using the Euclidean distance 
as the similarity metric and the complete linkage method 
as the between-cluster distance metric.
survival-associated mirna analysis
The TCGA ovarian dataset consisted of 479 samples that 
had clinical information data with miRNA expression and 
of these, 90 patients were classified as chemo-resistant and 
195 patients were categorized as chemo-sensitive. To identify 
miRNAs whose expression most strongly correlated with 
survival, each sample was assigned to two groups based on 
the expression of each miRNA: a low expression group and 
a high expression group. We then performed Kaplan–Meier 
survival analysis (Kaplan–Meier plots vs survival times, log-
rank t-test ,0.05) and estimated the survival distributions 
and used the log-rank test to assess the statistical significance 
of the differences between the stratified survival groups 
using GraphPad Prism (v5; GraphPad Software, San Diego, 
CA, USA).27,28
Results
Profiles of miRNAs in ovarian cancer 
cells and normal ovarian cells
To identify genome-wide miRNA expression patterns that 
could be useful to classify ovarian cancer cells from normal 
ovarian cells, we first analyzed the Illumina miRNA bead 
array using five human ovarian cancer cell lines (KF, KFr-
Tx, TUOS-3, TUOS-4, and SKOV3) and two human normal 
ovarian cell lines (IOSE386, IOSE397). The total RNA 
extracted from ovarian cancer cells and normal ovarian cells 
was hybridized with miRNA array chips. The expression-
detection P-value of Illumina Expression BeadChips was 
used to quantify the number of miRNA detected in the cell 
lines, designed to test the null hypothesis that the expression 
intensity of a given miRNA is indistinguishable from the 
background intensity. Individual miRNAs were examined 
using the detection P-value metric provided by Illumina, in 
which the signal generated from each miRNA is compared to 
negative controls. miRNAs that did not reach this threshold 
were eliminated from the analysis. Among a total of 1,145 
miRNAs profiled by the chips, 556 miRNAs passed the ini-
tial filters and were selected. We employed an unsupervised 
hierarchical clustering based on the variation of expression for 
each miRNA across the specimens (Figure S1 and Table S1). 
After this step, we selected only those miRNAs with P,0.01. 
This analysis identified 45 upregulated miRNAs and 37 
downregulated miRNAs, compared with the control, and 
allowed the robust segregation of two groups (Figure S2A and 
Table S2). The clustering results demonstrated that the lists 
of differentially expressed miRNAs might serve as potential 
biomarkers in ovarian cancer detection. As shown in Table 2, 
the highly overexpressed miRNAs in the ovarian cancer cells 
included miR-141, miR-106a, miR-200c, miR-96, and miR-
378. Highly underexpressed miRNAs in the ovarian cancer 
cells included miR-411, miR-432, miR-494, miR-409-3p, 
and miR-655. miRNAs can regulate a large number of target 
genes and several databases based on various algorithms 
are available for predicting the targets of selected miRNAs. 
MiRTar and PicTar were used to predict the target genes of 
the deregulated miRNAs with a mean fold-change .5.0. 
Table S3 lists the predicted targets among a large number of 
target genes. In order to validate the target gene expression, 
qRT-PCR was performed on several genes found to be targets 
of the miRNAs (Figure S2B) using each gene-specific primer 
pair. The expression ratio of cancer to normal cell IOSE386 
was calculated by using C
T
 and then was log
2
 transformed. 
While the absolute values were different, the trends were 
similar. ARID3B, KIAA1196, LIN28B, and NFIB were 
overexpressed in the ovarian cancer cells, while ACVR2B 
and HMGA2 were underexpressed in these cells. DLL1 and 
ROR1 were cell line-specific in these cells (Figure S3). These 
analyses demonstrated that ovarian cancer cells contain a 
large amount of detectable miRNAs that provide a valuable 
repertoire that could be used to discover drug-resistant miRNA 
as a biomarker signature for ovarian cancer.
Profiles of miRNAs in Taxol-sensitive  
and -resistant ovarian cancer cells
To search for the critical miRNAs involved in Taxol resis-
tance, Taxol-sensitive versus Taxol-resistant miRNA expres-
sion comparisons were conducted for four ovarian cancer 
Drug Design, Development and Therapy 2014:8
Table 2 Differentially expressed mirnas
P-value Fold-change** Unique ID P-value Fold-change Unique ID
1.00e-07 0.11 hsa-mir-770-5p 0.000663 0.03 hsa-mir-485-3p
1.00e-07 0.01 hsa-mir-370 0.000678 2.23 hsa-mir-186
4.00e-07 0.02 hsa-mir-369-3p 0.000732 3.53 hsa-mir-500
4.00e-07 0.02 hsa-mir-656 0.000758 1.69 hs_152
2.40e-06 0.01 hsa-mir-655 0.000774 0.12 hsa-mir-381
3.70e-06 0.02 hsa-mir-299-5p 0.00078 2.09 hsa-mir-769-5p
4.00e-06 0.03 hsa-mir-431 0.00085 3.20 hs_260
1.16e-05 0.03 hsa-mir-487a 0.000961 0.54 hs_221
1.18e-05 0.09 hsa-mir-136 0.001359 0.84 hsa-mir-448
1.45e-05 0.37 hsa-mir-299-3p 0.001376 105.60 hsa-mir-141
1.67e-05 0.01 hsa-mir-432 0.001413 2.22 hs_71.1
2.13e-05 0.12 hsa-mir-496 0.001418 70.02 hsa-mir-106a
3.67e-05 0.06 hsa-mir-539 0.001446 0.03 hsa-mir-154
4.03e-05 0.01 hsa-mir-379 0.001489 0.03 hsa-mir-495
4.40e-05 19.35 hsa-mir-96 0.001511 0.76 hs_132.1
6.17e-05 0.01 hsa-mir-494 0.001544 1.70 hsa-mir-507
7.35e-05 0.22 hs_155 0.001698 1.63 hs_20
8.85e-05 3.21 hs_52 0.001787 0.06 hsa-mir-154*
9.18e-05 0.06 hsa-mir-376a* 0.001986 0.02 hsa-mir-329
0.0001018 0.01 hsa-mir-411 0.002001 1.48 hsa-mir-614
0.000103 0.03 hsa-mir-376a 0.002272 2.57 hs_96
0.0001823 1.45 hs_200 0.002376 3.06 hsa-mir-769-3p
0.0001878 0.04 hsa-mir-409-5p 0.00267 0.14 hsa-mir-376b
0.0001902 0.35 hs_250 0.002716 1.26 hsa-mir-558
0.0002087 14.42 hsa-mir-378 0.002792 1.45 hsa-mir-564
0.0002531 0.26 hsa-mir-432* 0.00304 0.01 hsa-mir-487b
0.0003038 7.81 hsa-mir-183 0.003324 1.96 hs_113
0.0003437 3.97 hsa-mir-643 0.003433 0.27 hsa-mir-377
0.0003633 0.03 hsa-mir-382 0.00348 21.09 hsa-mir-200c
0.0004097 1.55 hsa-mir-206 0.003556 0.03 hsa-mir-410
0.0004121 2.09 hsa-mir-449b 0.003697 0.56 hs_58
0.0004409 0.12 hsa-mir-452* 0.003776 2.10 hs_304_a
0.0004779 5.52 hsa-mir-107 0.004131 1.13 hs_107
0.0004876 0.01 hsa-mir-409-3p 0.004294 1.29 hs_144
0.0004927 4.83 hsa-mir-182 0.004438 1.54 hs_219
0.0005116 0.02 hsa-mir-134 0.004668 1.47 hs_23
0.0005749 0.18 hsa-mir-485-5p 0.006323 1.32 hs_267
0.0005951 4.96 hsa-mir-182* 0.006329 1.65 hs_268
0.0006203 0.07 hsa-mir-433 0.006384 8.02 hsa-mir-604
0.0006261 0.52 hsa-mir-585 0.006832 0.58 hs_72
0.0006611 2.51 hs_244 0.008663 0.76 hs_111
Note: **Fold ratio of each miRNA in five ovarian cancer cells in comparison with normal ovarian cells.
Abbreviation: mirna, micro rubonucleic acid.
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cell lines. Taxol resistance was confirmed using MTT assay. 
We showed growth inhibition effects of Taxol on several cell 
lines (Figure S4). Measurement of mitochondrial metabolic 
rate using MTT to indirectly reflect viable cell numbers has 
been widely applied. It could be suggested that the metabolic 
activity of the cells may not be changed by Taxol treatments 
which can cause considerable variation in results. We first 
analyzed the detection P-value of Illumina Expression Bead-
Chips to determine differentially expressed changes in the 
Taxol-sensitive and -resistant ovarian cancer cells. Using this 
method, we identified 17 miRNAs at the significance level 
of P,0.05 (Table 3). This approach including seven upregu-
lated and ten downregulated miRNAs, was able to robustly 
segregate two prognosis groups (Figure 1A). qRT-PCR was 
performed to confirm miRNA expression  patterns in this 
study. As shown in Figure 1B, several miRNAs (miR-622, 
miR-647, and miR-663) confirmed the patterns obtained from 
the microarray and showed the consistency of the assays in 
KF/KFr-Tx and TUOS-3/TUOS-4. These three miRNAs were 
also confirmed to be upregulated in these Taxol-resistant 
cells, compared with normal IOSE386 and IOSE397 cells 
(Figure S5A). However, there was no significant regulation 
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Table 3 Differentially expressed mirnas
P-value Mean  
intensities  
in Taxol- 
resistant cells
Mean  
intensities  
in Taxol- 
sensitive cells
Fold-
change**
Unique ID
0.0497 318.89 123.26 2.59 hsa-mir-411
0.0104 6,390.04 2,948.43 2.17 hsa-mir-663
0.0062 328.87 1,56.59 2.10 hsa-mir-622
0.0101 681.41 371.67 1.83 hsa-mir-647
0.0261 152.88 84.61 1.81 hsa-mir-376a*
0.0146 3,386.01 1,912.99 1.77 hs_188
0.0479 349.69 240.54 1.45 hs_254
0.0463 3,602.12 5,224.86 0.69 hsa-mir-589
0.0298 209.63 315.59 0.66 hsa-mir-517*
0.0199 10,188.59 16,082.29 0.63 hsa-mir-107
0.0122 591 1,040.64 0.57 hs_279_a
0.0360 477.86 835.88 0.57 hs_160
0.0374 1,912.99 3,383.59 0.57 hsa-mir-195
0.0101 318.08 566.68 0.56 hsa-mir-187
0.0432 1,258.29 2,589.12 0.49 hs_303_b
0.0319 2,364.5 7,732.36 0.31 hsa-mir-363
0.0109 462.61 1,687.21 0.27 hsa-mir-497
Note: **Fold ratio of each mirna in Taxol-resistant cells in comparison with Taxol-
sensitive cells.
Abbreviation: mirna, micro rubonucleic acid.
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Figure 1 Differential mirna expression signatures between two Taxol-resistant cells and two Taxol-sensitive cells.
Notes: (A) We identified 17 miRNAs at the significance level of P,0.05. This approach included seven upregulated and ten downregulated mirnas that were able to 
robustly segregate two prognosis groups. To understand the mirna interactions and visualize the relationship, a heat map was made on the basis of their expression. each 
mirna is presented in matrix format, where rows represent individual mirna, respectively, and columns represent each ovarian cell. each cell in the matrix represents the 
expression level of a miRNA in an individual cell line. Red and green cells reflect high and low expression levels, respectively. (B) in vitro mirna expression patterns were 
mapped using eight Taxol-sensitive and -resistant ovarian cancer cells. in order to validate the data, the expression of mirna in each cell line was examined by qrT-Pcr. The 
results are presented as transcript levels relative to the level in each parental sensitive cell line by using the cT method. Taxol (sigma-aldrich, st louis, MO, Usa).
Abbreviations: mirna, micro rubonucleic acid; cT, threshold cycle; qrT-Pcr, quantitative reverse transcription-polymerase chain reaction.
in A2780/A2780-Tx and SKOV3/SKOV3-Tx. Only miR-622 
was upregulated in C13 Taxol-sensitive cells, compared with 
normal IOSE386 and IOSE397 cells (Figure S5B and C). 
The trend of expression alteration of these miRNAs showed 
a cell line-specific effect.
miR-663, miR-622, and HS_188, which were overex-
pressed in Taxol-resistant cells, might have oncogene-like 
functions.4,29,30 Of the underexpressed miRNAs, miR-497, miR-
187, miR-195, and miR-107 might have tumor suppressor-like 
functions (detailed in the ‘Discussion’ section).5,31–34 Remark-
ably, there are only three miRNAs (miR-411, miR-376a*, and 
miR-107) overlapping from the differentially expressed 82 
miRNAs. While miR-107 was underexpressed in the resistant 
cell lines compared to sensitive cells, it was overexpressed in 
the ovarian cancer cell lines compared to the normal ovarian 
cells. Both miR-411 and miR-376a* were overexpressed in 
the normal ovarian cells as shown in Table 2. As a result of this 
multiphase analysis, we selected a profile of 17 miRNAs to be 
the potential signature for Taxol resistance. Table S4 also lists 
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the predicted targets among a large number of target genes 
according to miRTar for each differentially expressed miRNA. 
In order to validate the data, qRT-PCR was performed on 
several genes found to be targets of miRNAs. As shown in 
Figure 2, IQSEC2, HRG22, FLOT2, LYPLA2, and NFIB 
were underexpressed in the Taxol- resistant ovarian cancer 
cells, while PAPSS2 was overexpressed in the Taxol-sensitive 
ovarian cancer cells. The trend of the expression alteration 
of KIAA1196, DLL1, RNF44, and VEZATIN showed a cell 
line-specific effect (Figure S6), indicating that the correla-
tion between miRNAs and Taxol resistance is not always 
consistent.
survival analysis for mirnas correlated 
with Taxol resistance
The TCGA ovarian dataset consisted of 479 patients samples 
for which clinical information data concerning miRNA 
expression were available. The clinical data were available 
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for the samples, including age, days to death, days to tumor 
progression, and age at initial pathologic diagnosis. To 
identify a biomarker signature of miRNAs whose expression 
most strongly correlated with survival, each patient sample 
was assigned to two groups based on the expression of each 
miRNA: a low expression group and a high expression group. 
We carried out survival analysis using the Kaplan–Meier plots 
and log-rank survival analyses in terms of up- and downregu-
lated miRNAs. The significant difference in overall survival 
(P,0.05) between the up- and downregulation groups was 
observed in 142 miRNAs (Table S5). The overall survival was 
increased with upregulation of 34 miRNAs including miR-
505, miR-652, miR-148a, and miR-let-7i (Figure 3A). On the 
other hand, overall survival was decreased with upregulation 
of 32 miRNAs including miR-320, miR-193b, miR-801, and 
miR-135a* (Figure 3B). These analyses demonstrate that 
several detectable miRNAs can be used to discover prognostic 
miRNA as a biomarker signature for ovarian cancer.
Survival analysis was also performed to identify 
miRNAs whose expression most strongly correlated with 
chemo-resistance. Following surgery, all patients received 
chemotherapy, which is considered the standard care for 
patients with advanced ovarian cancer. The patients showing 
either progression during chemotherapy or relapse within 
6 months of treatment are considered chemo-resistant. 
Among the aforementioned 479 patients, 90 patients 
were classified as chemo-resistant and 195 patients were 
categorized as chemo-sensitive.35 The median survival of the 
chemo-sensitive group was markedly longer (43.72 months) 
than that of the chemo-resistant group (28.13 months). To 
consider chemo-resistance and miRNA expression simulta-
neously in the prediction of overall survival, Kaplan–Meier 
survival analysis was carried out with expression infor-
mation of miRNAs and chemo- resistance information of 
the patients. The significant difference in overall survival 
(P,0.05) between up- and downregulation of miRNAs was 
observed in 129 miRNAs and 70 miRNAs in the sensitive and 
resistant patient groups, respectively (Table S6 and Table S7). 
In this analysis, only miR-136 showed longer survival with 
underexpression compared to overexpression in the sensi-
tive and resistant group (Figure S7). In comparison with the 
miRNAs in Table 3, Kaplan–Meier analysis demonstrated the 
significant difference between over and underexpression of 
the resistant group in two miRNAs including miR-663, and 
miR-622 (Figure 4), while the expression difference of the 
two miRNAs showed no significant effects in the sensitive 
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group. Only miR-647 showed slight significance between 
over- and underexpression in the sensitive group, while it 
showed no significance in the resistant group. Thus, in the 
case of miR-663 and miR-622, the less expressed, the longer 
the patient survived (more than 1 year of median survival) 
in the chemo-resistant group. Also, regarding miR-647, the 
more expressed, the longer the patient survived in the chemo-
sensitive group. The differential expressions of the miRNAs 
are identified from the training dataset, but have not been 
validated with external dataset. Therefore, to have prediction 
power for Taxol resistance of ovarian cancer, we validated 
the prediction power of the differentially expressed miRNAs 
using cross validation using a smaller number of dataset 
(Figure S7). Taken together, the overall survival of patients 
carrying chemo-resistance markedly would be increased with 
a treatment for the underexpression of these two miRNAs, 
while the chemo-sensitive patients with overexpression of 
miR-647 would show good prognosis. These results suggest 
that the differential expressions of the miRNAs are reliable, 
and that several miRNAs may play a role in Taxol resistance 
of ovarian cancer cells.
Differential correlations of mir-663,  
mir-622, and mir-647 with p53 networks
We used TargetScan Context Score, in silico miRNA target 
prediction algorithms and identified targets of miR-663, 
miR-622, and miR-647. For each miRNA, we first identified 
the putative miRNA target sites predicted by the TargetScan 
miRNA target prediction database (context score #-0.5) 
(Table S8, Table S9 and Table S10) and found that there are 
several p53 interactors. It is well known that p53 acts as a 
key regulator of ovarian cancer. In order to investigate the 
connection between miRNAs targeting of p53 network and 
Taxol resistance, we first performed a Western blot for the 
basal level of p53 networks. As shown in Figure 5, Taxol 
resistance cells (A2780-Tx and KFr-Tx) reduced the basal 
expression of p53, while its interacting targets, including 
p21, Rb, and PTEN, were reduced only in A2780-Tx. p21 
has higher expression in two Taxol-resistant ovarian cancer 
cells (KFr-TX and KOC-7C), suggesting that p21 expression 
can be regulated independently of p53. However, Taxol resis-
tance did not enhance the basal expression of CDK2, Cyclin 
D1, and CDK4. The basal expression of MDM2 was only 
enhanced in A2780-Tx and KFr-Tx. p53-null SKOV-3 cells 
did not show any basal expression of p53 and its interacting 
targets, including p21 and Rb. This analysis showed that sev-
eral proteins of p53 networks were differentially expressed 
in the Taxol-resistant cells compared to both parental Taxol-
sensitive cells, suggesting that Taxol resistance selectively 
blocks the p53 networks and showed cell line-dependency. 
Thus, the p53 pathway as a molecular signature in the Taxol 
resistance showed a different feature of expression pattern of 
each of the interactors, suggesting different interaction pat-
terns of the p53 networks in each ovarian cancer cell line.
To investigate if there is any association in the interac-
tion networks of p53 with three miRNAs in Taxol resis-
tance, we selected several target genes of the miRNAs 
from the latest version of the TargetScan (Release 6.2) 
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that can directly/indirectly interact with p53 (Table S11). 
Then, we performed qRT-PCR using each gene-specific 
primer pair. As shown in Figure 1B, three miRNAs were 
highly overexpressed in KFr-Tx and TUOS-4, compared to 
each parental sensitive cell line. While the absolute values 
were different, the inhibition effects of these miRNAs on 
the target genes were consistent, especially in TUOS-3 and 
TUOS-4 (Figure 6). TP53I1NP1, RRM2B, and DPP9 were 
downregulated in both KFr-Tx and TUOS-4. Several target 
genes were only downregulated in TUOS-4, while these 
were overexpressed in KFr-Tx. Thus, five target genes, 
including EEF1A2, FKBP8, NRARP, PDRG1, and JMY, 
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were showing the cell line-specific inhibition effects of these 
miRNAs. It was noted that while three miRNAs were rela-
tively  overexpressed in A2780-Tx and SKOV3-Tx, as shown 
in Figure 1B, we could detect significant downregulation of 
these target genes in A2780-Tx and SKOV3-Tx  (Figure S8) 
compared to each parental sensitive cell line. Taken together, 
the results showed cell line-specific inhibition of the highly 
interconnected network of p53 by the miRNAs, which sug-
gested that the specific difference of the interconnections of 
p53 might have important roles in Taxol-resistance of subtype 
patients in ovarian cancer.
To investigate if there is an association pattern in the 
interaction networks of other miRNAs with three miRNAs 
in 572 TCGA ovarian cancer tissue samples, we used Regu-
lome Explorer, which facilitates the integrative exploration 
of associations in clinical and molecular TCGA data by 
providing a wide-ranging view of connections between muta-
tions, expression level changes, and clinical outcomes.36 The 
molecular data included all of the miRNA expression levels 
of high-throughput data. We selected two miRNA (miR-663 
and miR-622) to explore any significant pairwise associa-
tions discovered within a heterogeneous dataset (Figures S9 
and S10). In the large number of pairwise tests, miR-215 
was selected as one of the most significant associations in a 
database for subsequent interactive exploration. The results 
of the miR-215 pairwise test include the number of samples 
used in the test, the Spearman correlation, and the –log10 
(P-value). Integrated Circos plot shows a predicted regulatory 
relationship between a miRNA and a miRNA, suggesting that 
both miR-663 and miR-622 regulate tens of miRNAs.
Discussion
Ovarian cancer is the most common cause of death among 
gynecologic malignancies. The 5-year survival rate in ovarian 
cancer patients with early stage cancer is about 50%–95%, 
and 11% in the advanced stages (III/IV).37 Despite an initial 
response rate of 65%–80% to first-line chemotherapy, most 
ovarian carcinomas relapse. Acquired resistance to further 
chemotherapy is generally responsible for treatment failure. 
The alteration of miRNA regulation has been implicated 
in carcinogenesis and disease progression.38 Most miRNA 
expression profiling studies of ovarian cancer have searched 
for differentially expressed miRNAs as novel drug targets 
relative to the corresponding normal control.39,40 Several 
studies with large datasets have also sought to identify an 
intricate array of genomic changes that correlate with clini-
cal outcome, to validate one specific change that occurs in 
the vast majority of all ovarian cancers.26,35 The possibility 
of miRNA expression profiles to predict outcomes in cancer 
patients has been shown.41 In particular, the miR-200 cluster 
has been associated with survival in ovarian cancer.16 Roles of 
miR-23a, -27a, -449b, -21, and -24-2* in response to chemo-
therapy in ovarian cancer tissues and cell lines have also been 
demonstrated and associated with chemo-responsiveness.42,43 
Another study showed that expression of miR-27a is upregu-
lated in the multidrug resistant (MDR) ovarian cancer cell line 
compared to its parental (A2780) cell line.44 These miRNAs 
may contribute to poor prognosis or chemotherapy resistance 
through their effect on their complexes. Some miRNAs, such 
as miR-29a, miR-31, miR-93, and miR-451, were found to 
be up- or downregulated in ovarian cancer cells character-
istic of altered or Cisplatin-resistant phenotype.12,26,45,46 But, 
the detailed mechanisms underlying resistance to Taxol in 
ovarian cancer cells are not understood.14 Only a few miRNA 
profiles have been reported with a potential involvement of 
miRNAs in the development of chemoresistance using a 
panel of paclitaxel-resistant (A2780TAX, A2780TC1, and 
A2780TC3) and cisplatin-resistant (A2780CIS) cell lines 
and showed downregulation of miRNA-30c, miRNA-130a, 
and miRNA-335 in all the resistant cell lines.14,47 It was also 
reported that genotypic differences lead to tissue-specific 
expression patterns3 and cell line-specific effects of miRNAs 
in ovarian cancer.45
In this study, we aimed to examine the role of miRNAs 
in Taxol resistance and to identify an oncogenic or tumor 
suppressor-like function involved in Taxol resistance. We 
identified 17 differentially expressed miRNAs using a panel of 
Taxol-resistant ovarian cancer cells with their Taxol-sensitive 
parental cells, and large set of TCGA ovarian data. Our data 
suggests that seven upregulated miRNAs (including miRNA-
411, miRNA-663, and miRNA-622) and ten downregulated 
miRNAs (including miRNA-497, miRNA-363, and miRNA-
303b) found in the Taxol-resistant ovarian cancer cells could 
contribute to the sensitivity of ovarian cancer cells. We recently 
found that several of the miRNAs that are overexpressed in 
Taxol-resistant cells were reported as having oncogene-like 
functions, such as miR-663, miR-622, and HS_188.4,29,30 Of 
the underexpressed miRNAs, several were reported as having 
tumor suppressor-like functions, such as miR-497, miR-187, 
miR-195, and miR-107.5,31–34 These miRNAs were involved 
in various biological processes, including apoptosis, signal 
transduction, and immune response. For example, miR-663 is 
associated with cancer.48 It was demonstrated that miR-663 is 
upregulated in nasopharyngeal carcinoma cells, and functions 
as an oncogene by promoting cell growth and tumorigenesis.29 
Furthermore, p21 was characterized as a direct and functional 
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target of miR-663. Among differently expressed miRNAs in 
pancreatic adenocarcinoma compared with chronic pancreatitis, 
miR-622 has not been related to the diagnosis of pancreatic 
cancer and is one of the most differentially expressed miR-
NAs.4 The association of the expression level of HS_188 with 
survival in the signatures was shown as highly predictive of 
the survival of stage I NSCLC patients, demonstrating that 
miRNA expression signatures combined with stage information 
has high classification power to predict the survival of stage I 
NSCLC patients.30 On the other hand, the expression level of 
miR-497 in breast cancer tissues is greatly decreased when 
compared with those in the normal adjacent tissue.31 miR-497 
has a similar function in tumor suppression in breast cancer 
that suppresses breast cancer cell proliferation and induces 
apoptosis. The tumor suppressor-like miR-187 is expressed 
at higher levels in ovarian cancers than in benign tumors.5 In 
patients with ovarian cancer, higher levels of miR-187 expres-
sion were paradoxically associated with better overall survival 
and recurrence-free survival, possibly through regulation of 
Dab2-mediated EMT. Downregulation of miR-195 has been 
observed in various types of cancers.49 The ectopic expression 
of miR-195 dramatically suppresses HCC cells to form colonies 
in vitro and to develop tumors in nude mice.32 Moreover, miR-
195 could block the G1/S transition and have functional targets 
of miR-195, including cyclin D1, CDK6, and E2F3. It was 
also reported that miR-107 is a miRNA expressed by human 
colon cancer specimens and regulated by p53.34 Also, miR-107 
could block hypoxic signaling by suppressing HIF-1β expres-
sion. These findings suggest that our in vitro study showed 
good consistency in oncogene-like and tumor suppressor-like 
functions, and the important role of those miRNAs in Taxol 
resistance with implications for cancer therapy.
Current methods of miRNA expression profiles provide 
several numbers of false positives. To narrow down the list 
of potential target of miRNAs, we used the intersection of 
the TCGA ovarian dataset, Kaplan–Meier plots, and log-rank 
survival analyses. An initial report from TCGA on high-grade 
serous ovarian adenocarcinomas presented a broad molecular 
signature of the disease relative to the corresponding normal 
control.35 We further investigated drug resistance-inducing 
miRNAs using the TCGA ovarian cancer clinical data (survival 
and recurrence status). Survival analysis based on miRNA 
expression profiles identified two groups showing a contrast in 
the expression pattern. One group including miR-505, miR-652, 
miR-148a, and miR-let-7i was upregulated with longer overall 
survival, while overall survival was increased with downregu-
lation of miRNAs including miR-320, miR-193b, miR-801, 
and miR-135a*. This was consistent with the observation that 
miR-148a inhibits proliferation in ovarian cancer cells and acts 
as a candidate tumor suppressor.3,50 In a paclitaxel-resistant 
NSCLC cell line, established either in vitro or in vivo, blockage 
of miR-135a sensitized resistant cell lines to paclitaxel-induced 
cell death.51 These miRNAs might be utilized as potential targets 
in patients with serous ovarian cancer.
The survival analysis demonstrated the significant differ-
ence between over and underexpression of miRNAs in the 
resistant patient group. The overall survival of patients carry-
ing chemo-resistance markedly increased with underexpres-
sion of several miRNAs. In particular, miRNA-663 and -622, 
which were upregulated in Taxol-resistant cancer cells in 
vitro showed better survival with downregulation, perhaps 
by increasing the sensitivity of cancer cells to Taxol. These 
miRNAs inhibit several interacting genes of p53 networks, 
especially in TUOS-3 and TUOS-4, and showed the cell 
line-specific inhibition effects. The most common subtype, 
high-grade serous carcinoma, is characterized by p53 muta-
tions. Thus, p53 appears impaired in ovarian cancer cell lines. 
However, it was reported that the cisplatin (and Taxol)-sensi-
tive cell line (KF), and three- and 30-fold cisplatin-resistant 
ovarian cancer cell lines (KFr and KFrP200) both showed no 
p53 mutation within exon 5, 6, 7, and 8.52 Thus, even though 
the expression level of p21 is not associated with p53 status 
in KF/KFr-Tx, it is likely that p53 was not impaired in the 
cells. Actually, p21 expression can be regulated independently 
of p53. It is consistent that miR-663 was found to be upregu-
lated in nasopharyngeal carcinoma (NPC) cells compared 
with human immortalized nasopharyngeal epithelium cells, 
and p21 was characterized as a direct and functional target 
of miR-663 to promote the cellular G1/S transition. As p21 
is regulated by p53-dependent and -independent mechanisms 
at the transcriptional level, we noted from the Western blot 
that miR-663 selectively blocks the p21 protein and shows 
cell line-dependency. The huge induction of p27 was noted 
in Taxol-resistant A2780-Tx. It was, however, reported that 
p27 expression can have an anti-apoptotic effect and prevent 
drug-induced apoptosis by DNA-damaging agents, such as 
cisplatin, leading to drug resistance.53 The effect of p27, there-
fore, may be cell or tissue specific.54 miR-663 also contributed 
to lung cancer cell proliferation by regulating TGFB1, P53, 
Bax, and Fas directly or indirectly.55 The overexpression of 
miR-663 was also reported in an induced multidrug-resistant 
MDA-MB-231/ADM cell line and the downregulation of 
miR-663 sensitized MDA-MB-231/ADM cells to both cyclo-
phosphamide and docetaxel in breast cancer.56
miR-622 was associated with differentiation and lymphatic 
metastasis formation both in vitro and in vivo of human gastric 
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cancer.57 miR-622 suppresses inhibitor of growth family, 
member 1 (ING1) expression that encodes a tumor suppres-
sor protein which is a nuclear protein that physically interacts 
with the tumor suppressor protein p53 and is a component of 
the p53 signaling pathway.58 Several studies have implicated 
miR-622 to be involved in EMT, to be related to the stem-cell-
like phenotype, and to be associated with a switch in paclitaxel 
responsiveness.59 Thus, it is logical to predict that the inhibition 
of these miRNAs may serve as a basis for the development of 
a potentially new therapeutic regimen against ovarian cancer. 
In the sensitive patient group, only miR-647 showed signifi-
cance between over- and underexpression on overall survival. 
The chemo-sensitive patients with  overexpression of miR-647 
showed good prognosis. Although little is known about miR-
647, this is one of the three genes in the predictive biomarker 
panel negatively associated with recurrence in prostate can-
cer,60 suggesting potential changes in DNA stability, PI3K 
signaling, p53 activity, apoptosis, and differentiation consistent 
with more aggressive disease. These results might implicate 
miRNA-associated chemo-resistance while the function of 
these miRNAs in ovarian cancer remains to be clarified.
Taken together, we found a set of miRNAs predictive 
of overall patient survival. As these miRNAs negatively 
or positively regulated predicted p53-related networks in a 
cell type-specific manner, the existence of a good classifier 
of Taxol resistance and cell line-specific miRNA function 
may play a role in the effects of chemo-preventive agents in 
ovarian cancer.
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Figure S5 Fold changes (ovarian cancer cells/normal ovarian cells) in mirna expression measured by qrT-Pcr.
Notes: (A) Three mirnas’ expression patterns in vitro using eight ovarian cancer cells and two normal ovarian cells. (B) Three mirnas’ expression patterns in vitro 
using two ovarian cancer cells and two normal ovarian cells. The results are presented as transcript levels relative to the level in the iOse386 cells by using the cT method. 
(C) Three mirnas’ expression patterns in vitro using two ovarian cancer cells. The expression of mirnas in each cell line was examined by qrT-Pcr. The results are 
presented as transcript levels relative to the level in each parental cell line by using the cT method.
Abbreviations: cT, threshold cycle; qrT-Pcr, quantitative reverse transcription-polymerase chain reaction; mirna, micro rubonucleic acid.
Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
311
micrornas associated with Taxol resistance
6
5
4
N
o
rm
al
iz
ed
 f
o
ld
 e
xp
re
ss
io
n
3
2
1
0
35
30
25
20
15
10
5
N
o
rm
al
iz
ed
 f
o
ld
 e
xp
re
ss
io
n
0
1.8
1.6
1.4
1.2
N
o
rm
al
iz
ed
 f
o
ld
 e
xp
re
ss
io
n
1.0
0.8
0.6
0.4
0.2
0.0
6,000
7,000
5,000
N
o
rm
al
iz
ed
 f
o
ld
 e
xp
re
ss
io
n
0
KIAA1196 DLL1
VEZATINRNF44
A2
78
0
A2
78
0-
Tx
SK
OV
3
SK
OV
3-
Tx KF
KF
r-T
x
TU
OS
3
TU
OS
4
A2
78
0
A2
78
0-
Tx
SK
OV
3
SK
OV
3-
Tx KF
KF
r-T
x
TU
OS
3
TU
OS
4
Figure S6 Fold changes (Taxol-resistant ovarian cancer cells/parental Taxol-sensitive cells) in gene expression measured by qrT-Pcr.
Notes: in vitro gene expression patterns using eight ovarian cancer cells. The expression of genes in each cell line was examined by qrT-Pcr. The results are presented as 
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Figure S7 mirna expression-dominant groups correlated with survival in Taxol resistance.
Notes: (A) Kaplan–Meier analysis showed that miR-136 has a significant difference between over- and underexpression of the resistant group and the sensitive group. 
(B) The differential expressions of the miRNAs were validated using cross validation using 75% of the dataset (68 patients as chemo-resistant). Red and blue reflect high and 
low expression levels, respectively. The difference between the two groups was significant when P,0.05. Taxol (sigma-aldrich, st louis, MO, Usa).
Abbreviation: mirna, micro rubonucleic acid.
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Figure S9 integrated view of mir-663 regulated by mirna.
Notes: (A) integrated circos plot shows mir-663 regulated by mirna. an ideogram of a normal karyotype is shown in the outer ring. in the center of the figure, each arc 
indicates a predicted regulatory relationship between mir-663 and a mirna. The colored arcs represent predicted regulation by key mirnas. (B) mir-663-mirna network 
shows the relationships that they are predicted to regulate.
Abbreviation: mirna, micro rubonucleic acid.
Figure S10 integrated view of mir-622 regulated by mirna.
Notes: (A) integrated circos plot shows mir-622 regulated by mirna. an ideogram of a normal karyotype is shown in the outer ring. in the center of the figure, each arc 
indicates a predicted regulatory relationship between mir-622 and a mirna. The colored arcs represent predicted regulation by key mirnas. (B) mir-622-mirna network 
shows the relationships that they are predicted to regulate.
Abbreviation: mirna, micro rubonucleic acid.
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